ArticleInternational journal of genomics2026
Targeting lncRNA PVT1/miR-145-5p/ABCC-1 Pathway Enhances Paclitaxel Sensitivity and Suppresses Melanoma Progression.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a highly aggressive type of skin cancer, melanoma cells show significant resistance against a variety of chemotherapeutics, such as paclitaxel, which limits the efficacy of the treatment. Studies have highlighted the potential role of noncoding RNA dysregulation in melanoma, affecting tumor progression and drug response, including lncRNA PVT1. Purpose: This study investigated whether simultaneous modulation of the lncRNA PVT1/miR-145-5p/ABCC1 axis enhances paclitaxel sensitivity and suppresses malignant behaviors in a melanoma cell line. Methods: Using SK-MEL-3 and A375 cells, we performed PVT1 knockdown using siPVT1, restored miR-145-5p function by transfection, and administered paclitaxel, either alone or in combination. Cell viability was assessed using the MTT assay; apoptosis and cell cycle distribution were analyzed by flow cytometry; and the expression of genes related to apoptosis, cell cycle regulation, migration, and drug resistance was quantified by qRT-PCR. Results: Combination therapy markedly reduced cell viability compared with single treatments. Cotargeting PVT1 and miR-145-5p significantly enhanced paclitaxel-induced apoptosis, evidenced by increased expression of proapoptotic and downregulation of antiapoptotic genes. The combination also induced a pronounced G1-phase arrest with decreased levels of CDK-4 and CDK-6. Furthermore, gene expression analysis showed downregulation of MMP-9 and ABCC1, along with upregulation of E-cadherin, suggesting reduced migratory potential and reversal of drug resistance. Conclusions: Simultaneous PVT1 knockdown and miR-145-5p overexpression enhance the anticancer effects of paclitaxel by promoting apoptosis, inducing cell cycle arrest, and mitigating drug resistance in melanoma cells. Targeting the PVT1/miR-145-5p/ABCC1 regulatory network may provide a promising therapeutic strategy to overcome chemoresistance in melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.